King Charles says Canada will stay ‘strong and free' as Trump talks 51st state
King Charles III provided an overview of the Legislature's priorities for Prime Minister Mark Carney's government and said that Canada will stay 'strong and free' in light of President Trump's talks about annexing the U.S.'s northern neighbor.
Charles, who is Canada's head of state, is the first British monarch to speak on the first day of Canadian Parliament in nearly 70 years.
'The 'True North' is indeed strong and free,' Charles said, in reference to Canada's national anthem.
'Every time I come to Canada, a little more of Canada seeps into my bloodstream and from there straight to my heart,' the monarch told the lawmakers on Tuesday. 'I've always had the greatest admiration for Canada's unique identity, which is recognized across the world for bravery and sacrifice in defense of national values and for the diversity and kindness of Canadians.'
Charles and Queen Camilla arrived in Canada, a member of the British Commonwealth, on Monday. The trip marked his first huddle with Canadian politicians since he became the head of state.
Charles did not directly name Trump, who has said he is serious about Canada becoming the U.S.'s 51st state, something Carney and other Canadian lawmakers have strongly rejected.
'Canada faces another critical moment. Democracy, pluralism, the rule of law, self-determination and freedom are values which Canadians hold dear and ones which the government is determined to protect,' Charles said Tuesday.
Trump's administration has imposed tariffs on Canada. The president has said that the U.S. will 'always' protect Canada militarily, even at the cost associated with it. The monarch said the North American neighbors are hashing out new agreements that will be beneficial for both sides.
The 'prime minister and the president of the United States, for example, have begun defining a new economic and security relationship between Canada and the United States, rooted in mutual respect and founded on common interests to deliver transformational benefits for both sovereign nations,' Charles said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
9 minutes ago
- Politico
A court halted his deportation. The Trump administration deported him 28 minutes later.
The Trump administration has admitted that it improperly deported another immigrant in violation of a court order — the fourth known case in which the administration deported someone erroneously or in breach of specific legal requirements. Jordin Melgar-Salmeron, an undocumented immigrant from El Salvador, had been in immigration detention since 2022 while deportation proceedings against him were pending. But on May 7, shortly after a federal appeals court ordered the government to keep him in the United States, immigration authorities deported him back to his native country. Matthew Borowski, a lawyer for Melgar-Salmeron, told POLITICO that he intends to ask the court to order the government to return his client from El Salvador and to hold government officials in contempt. In court papers this week, officials blamed a 'confluence of administrative errors,' including missed emails and an inaccurate roster of passengers on the May 7 deportation flight. The Justice Department declined to comment, and the Department of Homeland Security did not respond to requests for comment. The deportation of Melgar-Salmeron was first reported by the Investigative Post, a nonprofit news outlet in western New York. The episode is reminiscent of three other deportations that courts have declared illegal or improper in recent months: In each of those other three cases, judges have ordered the administration to try to bring the deportees back to the United States so that they can receive due process. The administration says it is working to return O.C.G. but has resisted the orders to return Abrego Garcia and Lozano-Camargo, claiming they are powerless because the men are in Salvadoran custody. Melgar-Salmeron, who spent years living in Virginia, had been in immigration detention since 2022 following a prison sentence for possessing an unregistered shotgun, according to court records. Though he had originally also been charged with entering the country illegally, he was allowed to plead guilty in 2021 to only the firearms charge. After his prison sentence ended, Melgar-Salmeron was detained by immigration authorities while deportation proceedings against him were ongoing. In January 2024, the Biden administration put Melgar-Salmeron's proceedings on hold amid broader litigation over immigration policy. But in April, the Trump administration moved to lift that hold, court documents show. Melgar-Salmeron had a longstanding appeal pending at the New York-based 2nd Circuit Court of Appeals. The administration asked the court to 'expedite' the appeal and indicated that it wanted to deport him by May 9 'at the latest' — but told the court it would not act before May 8. On the morning of May 7, a three-judge panel of the court ordered the government to keep Melgar-Salmeron in the United States while he pursued claims about fear of torture in his home country. Despite the court's order, Immigration and Customs Enforcement officials at a staging facility in Louisiana loaded Melgar-Salmeron onto a plane and deported him to El Salvador. The flight departed at 10:20 a.m. — 28 minutes after the court's order. Melgar-Salmeron is now in a Salvadoran prison, Borowski says. When the court learned about the deportation, it sent pointed questions to the administration about what had happened. The court demanded sworn declarations from ICE officials responsible for the man's deportation and an explanation of why the court's order to block his deportation was apparently not conveyed to the people who put him on the flight to El Salvador. The judges noted that the administration had assured them that Melgar-Salmeron would not be deported until at least May 8. They demanded to know why his deportation was abruptly advanced to May 7 less than an hour after their order. In a letter to the court on Wednesday, the administration acknowledged that the deportation was erroneous. Kitty Lees, a Justice Department attorney, said there had been a breakdown at multiple levels of the process. 'Several inadvertent administrative oversights led to Petitioner's May 7, 2025 removal,' Lees wrote, 'despite the express assurance made by the Government to this Court that it would forbear removing Petitioner until May 8, 2025.' Among the errors: The haphazard circumstances around Melgar-Salmeron's case bear some of the same hallmarks of other high-profile deportations that judges have sought to reverse. In March, the administration deported Abrego Garcia to El Salvador despite a 2019 immigration court order that barred the government from sending him there because he could be at risk of violence at the hands of a local gang. A Justice Department lawyer acknowledged in court that the deportation had been improper, and a federal judge ordered the administration to facilitate his release from El Salvador's custody. The Supreme Court largely upheld that requirement and noted that the deportation had been 'illegal.' A different federal judge has also ordered the administration to facilitate the return of Lozano-Camargo, who was deported to El Salvador in violation of a court-approved settlement agreement that protected certain immigrants who came to the U.S. as minors. (He is referred to in court papers with a pseudonym, but POLITICO previously identified him as Lozano-Camargo.) Abrego Garcia and Lozano-Camargo remain in Salvadoran prisons. The Trump administration has claimed in court that it has no ability to force the Salvadoran government to return them to United States custody. The administration, however, says it has taken steps to arrange a flight to bring back O.C.G., the Guatemalan man who was deported to Mexico in February. The man claims he was raped and otherwise targeted for being gay during a previous stay in Mexico. Administration officials initially claimed in court that he was given a chance to raise fears about being sent back to Mexico, but they later retracted that assertion and admitted they have no evidence that he was ever asked about whether he feared violence there. A federal judge ruled that O.C.G. had been deported without proper due process and ordered the government to facilitate his return.
Yahoo
9 minutes ago
- Yahoo
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented [212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatment Four of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject to confirmation. Seven of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up Perspective will hold a conference call on Monday, June 2, 2025 at 8:00 am ET SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. This Phase 1/2a clinical trial is a multi-center open-label dose escalation and dose expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapy (RPT) and whose tumors have shown radiological evidence of disease progression in the 12 months prior to enrollment. Updated interim efficacy data were presented for two patients in Cohort 1 and seven patients in Cohort 2 with a data cut-off date of April 30, 2025. These patients were enrolled for dose limiting toxicities observations. Results with a data cut-off date of January 10, 2025 from these patients were previously presented as a poster at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) in January 2025. Cohort 2 was reopened for enrollment in August 2024, and through April 30, 2025, a further 33 patients were enrolled in Cohort 2 and had received at least one treatment. Safety data were presented at the ASCO Annual Meeting for all 42 patients who had received at least one treatment with [212Pb]VMT-α-NET. Safety findings based on 42 patients who received at least one treatment: As of the data cut-off date of April 30, 2025, no dose limiting toxicities (DLTs), no discontinuations due to adverse events, no Grade 4 or 5 treatment emergent adverse events (TEAEs), and no deaths had been reported since the start of the study. Ten patients had experienced at least one Grade 3 TEAE; the majority of Grade 3 TEAEs were deemed unrelated to [212Pb]VMT-α-NET. Two patients experienced serious adverse events (SAEs), both of which were deemed unrelated to [212Pb]VMT-α-NET. A modest number of patients experienced low grade hematologic toxicities. Observations of lymphocyte count decrease were generally low grade, with three events at Grade 3 and none at Grades 4 or 5. Increases in blood creatinine levels were all at Grade 1. No dysphagia or serious renal complications were reported. Further anti-tumor activity observed in the nine original patients with longer follow-up. As of the data cut-off date of April 30, 2025, there was one new response pending confirmation, and three confirmed responses as defined by RECIST v1.1 in Cohort 2. Seven out of nine patients in Cohorts 1 and 2 continued to experience disease control and remained in study. One patient experienced stable disease for 48 weeks after their first dose prior to experiencing progressive disease. One patient was previously reported to have progressive disease after one dose under RECIST v1.1, by unambiguous progression of non-target lesions. The first patient who experienced a confirmed objective response remained in response for over 10 months and in study. This patient received the first two [212Pb]VMT-α-NET doses at administered dose of 5.0 mCi (equivalent to 84.6 µCi/kg), then received the remaining two doses at the next lower activity level of 2.5 mCi (equivalent to 42.4 µCi/kg). Two patients experienced initial responses after the end of their treatment periods as of the data cut-off date for the previous data presentation at ASCO-GI. Those responses have since been confirmed in subsequent scans. They remained in response and in study. These patients received four doses of 5.0 mCi (equivalent to 68.7 µCi/kg and 31.7 µCi/kg) of [212Pb]VMT-α-NET. A fourth patient was observed to experience an initial (unconfirmed) response in the seventh scan at 48 weeks after their first dose, which was the third scan conducted after the end of their treatment period. This patient received four doses of 5.0 mCi (equivalent to 49.1 µCi/kg) of [212Pb]VMT-α-NET. As stated in our August 12, 2024 business update for the second quarter of 2024, the observation period was completed for DLTs in seven patients enrolled in Cohort 2 during the second quarter of 2024. With no DLTs observed and minimal toxicity overall, the Safety Monitoring Committee (SMC) recommended proceeding with dose escalation and enrolling additional patients at 5 mCi to better understand efficacy and safety. Based on interactions with the U.S. Food and Drug Administration (FDA) prior to the initiation of patient dosing in this study in late 2023, the decision to dose patients in the next cohort will follow consultation and alignment with the FDA. "[212Pb]VMT-α-NET is emerging as an exciting potential treatment option for patients with progressive NETs, with continued durability of anti-tumor activity at the dose level used in Cohort 2 and a favorable tolerability profile seen so far," said Vikas Prasad, MD, Associate Professor of Radiology, Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University School of Medicine. 'I am eager to find more treatments to help my patients fight hard against their disease and return to their normal lives. I look forward to continuing to evaluate [212Pb]VMT-α-NET as a new option to help my patients, by participating in this study.' Markus Puhlmann, Chief Medical Officer of Perspective, commented, 'We are encouraged by the exciting overall clinical profile already observed at the dose level used in Cohort 2. The robust participation in the re-opened Cohort 2 in this dose finding study of [212Pb]VMT-α-NET enables us to learn more about how [212Pb]VMT-α-NET can benefit patients and fit into the current treatment paradigm. We plan to submit longer safety follow-up data for all patients enrolled in the study and preliminary efficacy data for a subgroup for presentation at a scientific congress in the second half of this year. In keeping with the commitment we made to the FDA prior to the start of dosing in this study, we are engaging with the FDA as we wish to continue to pursue dose finding for [212Pb]VMT-α-NET. An update will be provided once alignment is reached with the agency.' Thijs Spoor, Chief Executive Officer of Perspective, commented, '[212Pb]VMT-α-NET is progressing expeditiously as one of three potential new medicines in clinical development based on our next generation targeted radiopharmaceutical technology platform. We continue to evaluate opportunities to enhance our operations and infrastructure so we can support patient demand for all of our programs.' Perspective will webcast a conference call on Monday, June 2, 2025 at 8:00 am ET to discuss the data presented at the ASCO Annual Meeting. Webcast details are available on the Events page of the Company's website. Dr. Prasad will participate, along with members of Perspective's management team. A live question and answer session will follow the formal presentation. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label dose escalation, dose expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT). Results with a data cut-off date of January 10, 2025 from the first nine patients enrolled into Cohorts 1 and 2 of the study were previously presented as a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) in January 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 patients enrolled after the cohort reopened and through April 30, 2025, will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Neuroendocrine TumorsNeuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors and as a result, there are over 170,000 people living with this diagnosis.1 About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the potential for [212Pb]VMT-α-NET to be a treatment option for and benefit patients with progressive NETs with durable anti-tumor activity and a favorable tolerability profile, including at the dose level administered to patients in Cohort 2 of the Company's [212Pb]VMT-α-NET study; the Company's belief that robust participation in the re-opened Cohort 2 in this dose finding study of [212Pb]VMT-α-NET will enable it to learn more about how [212Pb]VMT-α-NET can benefit patients and fit into the current treatment paradigm; the potential for treatments such as [212Pb]VMT-α-NET to help patients fight hard against their disease and return to their normal lives; the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of additional data from the Company's clinical trials; the Company's anticipated timing and expectations regarding regulatory communications, requests, interactions, submissions, alignment, and approvals, including the Company's expectation that it will reach an alignment with the FDA on dose-finding for [212Pb]VMT-α-NET; the Company's activities and plans to pursue dose escalation for its Phase 1/2a clinical trial of [212Pb]VMT-α-NET; the Company's plans to enhance its operations and infrastructure to support patient demand for all of its programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@ 1 Wu P, He D, Chang H, Zhang X. Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA. Endocr Connect. 2023;12(12):e230331. Published 2023 Nov 23. doi:10.1530/EC-23-0331.
CNN
9 minutes ago
- CNN
Fareed Zakaria breaks down Trump's tariff battle
Fareed Zakaria breaks down Trump's tariff battle CNN's Fareed Zakaria breaks down what's going on with President Donald Trump's battle with the Supreme Court over tariffs. 00:58 - Source: CNN Trump responds to Wall Street term 'TACO': Trump Always Chickens Out President Donald Trump was asked about "TACO," an acronym that means "Trump Always Chickens Out," which is used by Wall Street workers for his on-and-off approach to tariffs. Calling it "the nastiest question," Trump defended his tariff policy by calling it "negotiation." 01:13 - Source: CNN President Trump is on a pardoning spree President Donald Trump used his pardon power to grant clemency to a wave of individuals who had been convicted of crimes that range from public corruption, guns and even maritime-related offenses, according to multiple officials. CNN's Kaitlan Collins reports. 00:53 - Source: CNN Harvard students and faculty speak out against Trump Harvard students and faculty spoke to CNN ahead of commencement as Donald Trump said the university should cap foreign enrollment. The Trump administration has recently sought to cancel $100 million in contracts with the school. 02:03 - Source: CNN Trump says new Russia sanctions could hurt peace talks President Donald Trump expressed concern that levying new sanctions against Russia in response to their continued strikes in Ukraine could jeopardize peace talks between the two nations. 00:51 - Source: CNN Trump voter may lose his job because of Trump policies CNN's John King visits one of the country's top targets of the 2026 midterms — Pennsylvania's 7th Congressional District — and speaks to a Trump voter who is in danger of being laid off due to the President's tariffs. 01:11 - Source: CNN He voted for the first time at 55. Hear why CNN's John King visits one of the country's top targets of the 2026 midterms — Pennsylvania's 7th Congressional District — and hears why, at 55, one man felt compelled to vote in a presidential election for the first time in his life. 01:04 - Source: CNN DEI leader: Trump's agenda 'instills fear' CNN's John King visits one of the country's top targets of the 2026 midterms — Pennsylvania's 7th Congressional District — where a leader of a DEI program tells him what she's doing to prepare for possible funding cuts. 00:48 - Source: CNN NYC Mayor Eric Adams defends Trump relationship New York City Mayor Eric Adams speaks with CNN's Maria Santana about his controversial relationship with President Donald Trump, which has garnered close attention after the Department of Justice recommended his criminal charges be dropped. 01:07 - Source: CNN Trump directs federal agencies to cancel Harvard contracts The White House is directing federal agencies to cancel all remaining contracts with Harvard University – about $100 million in all, two senior Trump administration officials told CNN – the latest barb against the school as it refuses to bend to the White House's barrage of policy demands amid a broader politically charged assault on US colleges. 01:15 - Source: CNN Finland's president responds to Russian military activity along border CNN's Erin Burnett speaks with Finland's President Alexander Stubb about his country ramping up its military to deter potential Russian aggression. 02:16 - Source: CNN Trump pardons reality TV couple Todd and Julie Chrisley President Donald Trump has signed full pardons for imprisoned reality show couple Todd and Julie Chrisley, who were sentenced to lengthy prison terms in 2022 for a conspiracy to defraud banks out of more than $30 million, according to a White House official. CNN's Kaitlan Collins reports. 01:07 - Source: CNN Trump: 'I don't know what the hell happened to Putin' Speaking to reporters before boarding Air Force One in Morristown, New Jersey, President Donald Trump said that he was 'not happy with what Putin is doing', after Moscow launched its largest aerial attack of its three-year full-scale war on Ukraine overnight. 00:50 - Source: CNN Trump visits Arlington National Cemetery on Memorial Day President Donald Trump honors fallen service members at Arlington National Cemetery on Memorial Day. 00:27 - Source: CNN Johnson pressed on Medicaid cuts in spending bill CNN's Jake Tapper asks House Speaker Mike Johnson about who will lose Medicaid under President Donald Trump's 'big, beautiful bill'. Johnson defends the proposed cuts and argues the changes target "waste, fraud and abuse." 01:30 - Source: CNN Is the U.S. on the brink of fiscal crisis? President Trump's economic agenda is expected to add nearly $4 trillion to the US national debt. CNN's Phil Mattingly breaks down what that could mean for the economy. 01:48 - Source: CNN Trump says Apple will face tariffs if it doesn't make iPhones in US President Donald Trump told reporters Apple and other cell phone manufacturers will face 25% tariffs unless they manufacture their products in the US during an event interrupted by Trump's own iPhone ringing multiple times. 01:11 - Source: CNN Trump hosts lavish dinner for meme coin investors More than 200 wealthy crypto bros gathered for a private event at President Donald Trump's golf club just outside Washington, DC, on Thursday night — dining on filet mignon and halibut while the president stood at a podium regaling them with tales of his 2024 victory. 01:33 - Source: CNN
